Renata Approved for German Market Entry with Parkinson Drug

Industry: Healthcare & Pharma, Pharma
Company: Renata Limited
Company Intelligence Tag: Business Insights

Renata Pharmaceuticals (Ireland) Limited, a subsidiary of Renata Limited in Europe, has received regulatory approval from the European Union (EU) and German authorities for its anti-Parkinson’s therapy, Cabergoletten 1mg and Cabergoletten 2mg. This marks the first of many approvals the company anticipates from the German Federal Institute for Drugs and Medical Devices (BfArM). Renata has a strong presence in the pharmaceutical markets of various countries, including Australia, the USA, Canada, the UK, and the EU, with over 25 approved products. With 64 bioequivalent products and operations in 40 countries, Renata emphasizes research and development, conducts clinical trials, and boasts 14 advanced manufacturing facilities. The company has successfully entered the EU and UK markets, and its global pharmaceutical footprint continues to expand, with plans to enter France, Norway, Denmark, Sweden, Spain, and Portugal.

Source for more details:

Related News

Square Pharma Chairman to Buy 15 Lakh Shares for Tk 32 Crore

March 11, 2025

Samuel S Chowdhury, chairman of Square Pharmaceuticals, plans to buy 15 lakh shares worth over Tk 32 crore within 30 working days through the Dhaka Stock Exchange (DSE). As of November 30, 2023, he held a 9.32% stake, which will rise to 9.49% after the purchase.

Pharma Exports Grow 7.1% in Eight Months of FY24-25

March 10, 2025

Bangladesh's pharmaceutical exports saw steady growth in the first eight months of FY24-25, earning $145.46 million, a 7.1% increase from $135.81 million in the same period of the previous year. Growth was driven by rising demand in developed markets like the US, Australia, and Europe.

Govt Provides Tk 525.46 Crore to Beximco for Worker Dues

March 8, 2025

The government has provided Tk 525.46 crore to Beximco Group to settle dues for workers and officials of 14 closed textile and garment units. The funds, allocated by the finance division, will be disbursed as a loan, which Beximco must repay later.

SC Allows Govt-Approved Directors to Rejoin Beximco Firms

March 5, 2025

The Appellate Division of the Supreme Court has allowed independent directors appointed by the Bangladesh Securities and Exchange Commission (BSEC) to resume duties at Beximco, Beximco Pharmaceuticals, and Shinepukur Ceramics.

NBR Slashes Source Tax for Cancer Drug Raw Materials to 2%

March 4, 2025

The National Board of Revenue (NBR) has reduced the source tax on the import of raw materials used in cancer drug production from 5% to 2%, aiming to lower production costs and make oncology medicines more affordable. This move is expected to benefit both pharmaceutical manufacturers and patients by reducing drug prices.

Beximco Green Sukuk Investors Worry About Principal Repayment

March 4, 2025

Investors in the Tk 3,000 crore Beximco Green Sukuk al-Istisna are increasingly concerned about recovering their principal as the issuer struggles with financial distress. The recent layoffs across 15 apparel units and Beximco’s Tk 50,000 crore in bank loans—more than half classified as non-performing—have intensified worries.

Related News

Square Pharma Chairman to Buy 15 Lakh Shares for Tk 32 Crore

March 11, 2025

Samuel S Chowdhury, chairman of Square Pharmaceuticals, plans to buy 15 lakh shares worth over Tk 32 crore within 30 working days through the Dhaka Stock Exchange (DSE). As of November 30, 2023, he held a 9.32% stake, which will rise to 9.49% after the purchase.

Pharma Exports Grow 7.1% in Eight Months of FY24-25

March 10, 2025

Bangladesh's pharmaceutical exports saw steady growth in the first eight months of FY24-25, earning $145.46 million, a 7.1% increase from $135.81 million in the same period of the previous year. Growth was driven by rising demand in developed markets like the US, Australia, and Europe.

Govt Provides Tk 525.46 Crore to Beximco for Worker Dues

March 8, 2025

The government has provided Tk 525.46 crore to Beximco Group to settle dues for workers and officials of 14 closed textile and garment units. The funds, allocated by the finance division, will be disbursed as a loan, which Beximco must repay later.

SC Allows Govt-Approved Directors to Rejoin Beximco Firms

March 5, 2025

The Appellate Division of the Supreme Court has allowed independent directors appointed by the Bangladesh Securities and Exchange Commission (BSEC) to resume duties at Beximco, Beximco Pharmaceuticals, and Shinepukur Ceramics.

NBR Slashes Source Tax for Cancer Drug Raw Materials to 2%

March 4, 2025

The National Board of Revenue (NBR) has reduced the source tax on the import of raw materials used in cancer drug production from 5% to 2%, aiming to lower production costs and make oncology medicines more affordable. This move is expected to benefit both pharmaceutical manufacturers and patients by reducing drug prices.

Beximco Green Sukuk Investors Worry About Principal Repayment

March 4, 2025

Investors in the Tk 3,000 crore Beximco Green Sukuk al-Istisna are increasingly concerned about recovering their principal as the issuer struggles with financial distress. The recent layoffs across 15 apparel units and Beximco’s Tk 50,000 crore in bank loans—more than half classified as non-performing—have intensified worries.

BUSINESSMONITOR

Connect with


Dont Have Account? Please register Here